1. Сахарный Диабет: "История Болезни" Сквозь Призму Научных Открытий в 2 Томах/И.И. Дедов, М.В. Шестакова [и др.]. - Москва: ООО "Медицинское Информационное Агентство", 2025. - Т. 1.

2. Redondo MJ, Fain PR, Eisenbarth GS. Genetics of type 1A diabetes. Recent Prog Horm Res. 2001; 56: 69 - 89.

3. Atkinson MA. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med. 2012; 2(11): a007641. doi: 10.1101/cshperspect.a007641.

4. Antvorskov JC, Josefsen K, Engkilde K, Funda DP, Buschard K. Dietary gluten and the development of type 1 diabetes. Diabetologia. 2014; 57(9): 1770 - 1780. doi: 10.1007/s00125-014-3265-1.

5. Kawasaki E. Type 1 diabetes and autoimmunity. Clin Pediatr Endocrinol. 2014; 23(4): 99 - 105. doi: 10.1297/cpe.23.99.

6. Lampasona V, Liberati D. Islet Autoantibodies. Curr Diab Rep. 2016; 16(6): 53. doi: 10.1007/s11892-016-0738-2.

7. International Diabetes Federation. IDF Diabetes Atlas. 11th Ed.; 2025 https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/.

8. Федеральная служба государственной статистики. Здравоохранение в России. Доступно по ссылке: https://rosstat.gov.ru/folder/210/document/13218.

9. World Health Organization, International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Report of a WHO/IDF Consultation. - Geneva, 2006.

10. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus. - Geneva, 1999.

11. World Health Organization. Classification of Diabetes Mellitus. World Health Organization. 2019.

12. Hansen MP. Type 1 diabetes and polyglandular autoimmune syndrome: A review. World J Diabetes. 2015; 6(1): 67. doi: 10.4239/wjd.v6.i1.67.

13. Дедов И.И., Шестакова М.В.. Сахарный Диабет Типа 1: Реалии и Перспективы. - МИА, 2016.

14. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1): S27 - S49. doi: 10.2337/dc25-S002.

15. Алгоритмы специализированной медицинской помощи больным сахарным диабетом/Под редакцией И.И. Дедова, М.В. Шестаковой, О.Ю. Сухаревой. - 12-й выпуск. - М., 2025.

16. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7): 1327 - 1334. doi: 10.2337/dc09-9033.

17. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. - Geneva, 2011.

18. Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016; 12(4): 222 - 232. doi: 10.1038/nrendo.2016.15.

19. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2024; 48 (Supplement_1): S59 - S85. doi: 10.2337/dc25-S004.

20. de Boer IH, DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014; 37(1): 24 - 30. doi: 10.2337/dc13-2113.

21. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139(2): 137 - 147. doi: 10.7326/0003-4819-139-2-200307150-00013.

22. James MT, Grams ME, Woodward M, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis. 2015; 66(4): 602 - 612. doi: 10.1053/j.ajkd.2015.02.338.

23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024; 105(4S): S117 - S314. doi: 10.1016/j.kint.2023.10.018.

24. , Corte Z, , et al. Systematic review of the biological variation data for diabetes related analytes. Clin Chim Acta. 2019; 488: 61 - 67. doi: 10.1016/j.cca.2018.10.031.

25. Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017; 8(3): 475 - 487. doi: 10.1007/s13300-017-0265-4.

26. Силко Ю.В., Никонова Т.В., Иванова О.Н., и др. Латентный аутоиммунный диабет взрослых: информативность аутоантител. Терапевтический архив. 2016; 88(10): 42 - 45. doi: 10.17116/terarkh2016881042-45.

27. Sosenko JM, Skyler JS, Palmer JP, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013; 36(9): 2615 - 2620. doi: 10.2337/dc13-0425.

28. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010; 53(12): 2504 - 2508. doi: 10.1007/s00125-010-1799-4.

29. Shepherd M, Sparkes AC, Hattersley AT. Genetic testing in maturity onset diabetes of the young (MODY): a new challenge for the diabetic clinic. Pract Diabetes Int. 2001; 18(1): 16 - 21. doi: 10.1002/pdi.108.

30. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ. 2011; 343: d6044. doi: 10.1136/bmj.d6044.

31. Shun CB, Donaghue KC, Phelan H, et al. Thyroid autoimmunity in Type 1 diabetes: systematic review and meta-analysis. Diabet Med. 2014; 31(2): 126 - 135. doi: 10.1111/dme.12318.

32. Jonsdottir B, Larsson C, Carlsson A, et al. Thyroid and Islet Autoantibodies Predict Autoimmune Thyroid Disease at Type 1 Diabetes Diagnosis. J Clin Endocrinol Metab. 2017; 102(4): 1277 - 1285. doi: 10.1210/jc.2016-2335.

33. Warncke K, Frohlich-Reiterer EE, Thon A, et al. Polyendocrinopathy in Children, Adolescents, and Young Adults With Type 1 Diabetes: A multicenter analysis of 28,671 patients from the German/Austrian DPV-Wiss database. Diabetes Care. 2010; 33(9): 2010 - 2012. doi: 10.2337/dc10-0404.

34. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977 - 986. doi: 10.1056/NEJM199309303291401.

35. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin JM, Genuth S, et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6): 381 - 389. doi: 10.1056/NEJM200002103420603.

36. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1): S128 - S145. doi: 10.2337/dc25-S006.

37. Общероссийская общественная организация "Российская ассоциация геронтологов и гериатров". Клинические рекомендации "Старческая астения". 2024.

38. Ткачева О.Н., Рунихина Н.К., Остапенко В.С., и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017; 30(2): 236 - 242.

39. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care. 2008; 31(8): 1473 - 1478. doi: 10.2337/dc08-0545.

40. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42(8): 1593 - 1603. doi: 10.2337/dci19-0028.

41. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019; 42(3): 400 - 405. doi: 10.2337/dc18-1444.

42. Beck RW, Bergenstal RM, Cheng P, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. J Diabetes Sci Technol. 2019; 13(4): 614 - 626. doi: 10.1177/1932296818822496.

43. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019; 21(2): 81 - 85. doi: 10.1089/dia.2018.0310.

44. Davis MR, Mellman M, Shamoon H. Further Defects in Counterregulatory Responses Induced by Recurrent Hypoglycemia in IDDM. Diabetes. 1992; 41(10): 1335 - 1340. doi: 10.2337/diab.41.10.1335.

45. Henriksen MM, Andersen HU, Thorsteinsson B, Pedersen-Bjergaard U. Hypoglycemic Exposure and Risk of Asymptomatic Hypoglycemia in Type 1 Diabetes Assessed by Continuous Glucose Monitoring. J Clin Endocrinol Metab. 2018; 103(6): 2329 - 2335. doi: 10.1210/jc.2018-00142.

46. Weinstock RS, DuBose SN, Bergenstal RM, et al. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care. 2016; 39(4): 603 - 610. doi: 10.2337/dc15-1426.

47. Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol. 2015; 52(5): 845 - 853. doi: 10.1007/s00592-015-0713-4.

48. Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. The Lancet. 2017; 390(10110): 2347 - 2359. doi: 10.1016/S0140-6736(17)32400-5.

49. Kristensen K, , Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia. 2019; 62(7): 1143 - 1153. doi: 10.1007/s00125-019-4850-0.

50. Fisher M. Statins for people with type 1 diabetes: when should treatment start? Pract Diabetes. 2016; 33(1): 10 - 11. doi: 10.1002/pdi.1990.

51. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet. 2008; 371(9607): 117 - 125. doi: 10.1016/S0140-6736(08)60104-X.

52. Rabar S, Harker M, O'Flynn N, Wierzbicki AS. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014; 349(12): g4356. doi: 10.1136/bmj.g4356.

53. Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012; 9(10): e1001321. doi: 10.1371/journal.pmed.1001321.

54. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326): 7 - 22. doi: 10.1016/S0140-6736(02)09327-3.

55. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111 - 188. doi: 10.1093/eurheartj/ehz455.

56. Hansen TW, Kikuya M, Thijs L, et al. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. J Clin Hypertens Greenwich Conn. 2008; 10(5): 377 - 381.

57. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013; (10): CD008277. doi: 10.1002/14651858.CD008277.pub2.

58. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. J Hypertens. 2017; 35(5): 922 - 944. doi: 10.1097/HJH.0000000000001276.

59. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009; 26(2): 142 - 148. doi: 10.1111/j.1464-5491.2008.02640.x.

60. , Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016; 352: i717. doi: 10.1136/bmj.i717.

61. Rawshani A, Rawshani A, , et al. Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2017; 135(16): 1522 - 1531. doi: 10.1161/CIRCULATIONAHA.116.025961.

62. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. The Lancet. 2016; 387(10017): 435 - 443. doi: 10.1016/S0140-6736(15)00805-3.

63. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024; 45(38): 3912 - 4018. doi: 10.1093/eurheartj/ehae178.

64. ГОСТ Р ИСО 15197-2015 Тест-системы для диагностики in vitro. Требования к системам мониторинга глюкозы в крови для самоконтроля при лечении сахарного диабета. Москва: Стандартинформ, 2015.

65. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001; 111(1): 1 - 9. doi: 10.1016/s0002-9343(01)00742-2.

66. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal Study of New and Prevalent Use of Self-Monitoring of Blood Glucose. Diabetes Care. 2006; 29(8): 1757 - 1763. doi: 10.2337/dc06-2073.

67. Parkin CG, Davidson JA. Value of Self-Monitoring Blood Glucose Pattern Analysis in Improving Diabetes Outcomes. J Diabetes Sci Technol. 2009; 3(3): 500 - 508. doi: 10.1177/193229680900300314.

68. Sheppard P, Bending J, Huber J. Pre- and post-prandial capillary glucose self-monitoring achieves better glycaemic control than pre-prandial only monitoring. Pract Diabetes Int. 2005; 22(1): 15 - 22. doi: 10.1002/pdi.733.

69. Vervoort G, Goldschmidt HMG, van Doorn LG. Nocturnal Blood Glucose Profiles in Patients with Type 1 Diabetes Mellitus on Multiple ( 4) Daily Insulin Injection Regimens. Diabet Med. 1996; 13(9): 794 - 799. doi: 10.1002/(SICI)1096-9136(199609)13:9<794::AID-DIA185>3.0.CO;2-G.

70. Louie RF, Lau MJ, Lee JH, et al. Multicenter Study of the Prevalence of Blood Contamination on Point-of-Care Glucose Meters and Recommendations for Controlling Contamination. Point Care J-Patient Test Technol. 2005; 4(4): 158 - 163. doi: 10.1097/01.poc.0000189933.35225.77.

71. Lewandrowski K. Point-of-care testing: an overview and a look to the future (circa 2009, United States). Clin Lab Med. 2009; 29(3): 421 - 432. doi: 10.1016/j.cll.2009.06.015.

72. Klonoff DC, Perz JF. Assisted Monitoring of Blood Glucose: Special Safety Needs for a New Paradigm in Testing Glucose. J Diabetes Sci Technol. 2010; 4(5): 1027 - 1031. doi: 10.1177/193229681000400501.

73. World Health Organization. WHO injection safety. Fact sheet No. 231. Revised May 2016. Geneva, 2016.

74. Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol. 2009; 3(2): 283 - 288. doi: 10.1177/193229680900300208.

75. Jovanovic L, Savas H, Mehta M, et al. Frequent Monitoring of A1C During Pregnancy as a Treatment Tool to Guide Therapy. Diabetes Care. 2011; 34(1): 53 - 54. doi: 10.2337/dc10-1455.

76. Gorst C, Kwok CS, Aslam S, et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care. 2015; 38(12): 2354 - 2369. doi: 10.2337/dc15-1188.

77. Ajjan RA, Cummings MH, Jennings P, et al. Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. Diab Vasc Dis Res. 2019; 16(1): 3 - 12. doi: 10.1177/1479164118795252.

78. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet. 2016; 388(10057): 2254 - 2263. doi: 10.1016/S0140-6736(16)31535-5.

79. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. JAMA. 2017; 317(4): 379 - 387. doi: 10.1001/jama.2016.19976.

80. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017; 40(12): 1631 - 1640. doi: 10.2337/dc17-1600.

81. , , , et al. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care. 2020; 43(11): 2744 - 2750. doi: 10.2337/dc20-0112.

82. Lodwig V, Heinemann L. Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria. Diabetes Technol Ther. 2003; 5(4): 572 - 586. doi: 10.1089/152091503322250596.

83. Heinemann L. Interferences With CGM Systems: Practical Relevance? J Diabetes Sci Technol. 2022; 16(2): 271 - 274. doi: 10.1177/19322968211065065.

84. , Jensch H, Cardinal C, et al. Laboratory Protocol and Pilot Results for Dynamic Interference Testing of Continuous Glucose Monitoring Sensors. J Diabetes Sci Technol. 2024; 18(1): 59 - 65. doi: 10.1177/19322968221095573.

85. Дедов И.И., Шестакова М.В., Петеркова В.А., и др. Проект рекомендаций Российской ассоциации эндокринологов по применению биосимиляров инсулина. Сахарный диабет. 2021; 24(1): 76 - 79.

86. Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013; 5(4): 482 - 491. doi: 10.1111/1753-0407.12060.

87. Wojciechowski P, Niemczyk-Szechowska P, , et al. Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewn. 2015; 125(3): 141 - 151.

88. Aronson R, Biester T, Leohr J, et al. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes Obes Metab. 2023; 25(7): 1964 - 1972. doi: 10.1111/dom.15063.

89. Heise T, Pieber TR, Danne T, et al. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clin Pharmacokinet. 2017; 56(5): 551 - 559. doi: 10.1007/s40262-017-0514-8.

90. Dawoud D, O'Mahony R, Wonderling D, Cobb J, Higgins B, Amiel SA. Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. Value Health. 2018; 21(2): 176 - 184. doi: 10.1016/j.jval.2017.04.024.

91. Szypowska A, Golicki D, Groele L, . Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewn. 2011; 121(7 - 8): 237 - 246.

92. Einhorn D, Handelsman Y, Bode BW, et al. Patients achieving good glycemic control (HbA1c < 7%) experience a lower rate of hypoglycemia with insulin degludec than with insulin glargine: a meta-analysis of phase 3a trials. Endocr Pract. 2015; 21(8): 917 - 926. doi: 10.4158/EP14523.OR.

93. , Golicki D, Kowalska A, Szypowska A. The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials. Acta Diabetol. 2015; 52(2): 231 - 238. doi: 10.1007/s00592-014-0604-0.

94. Russell-Jones D, Gall MA, Niemeyer M, et al. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis. 2015; 25(10): 898 - 905. doi: 10.1016/j.numecd.2015.06.005.

95. Laubner K, Molz K, Kerner W, et al. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database. Diabetes Metab Res Rev. 2014; 30(5): 395 - 404. doi: 10.1002/dmrr.2500.

96. Laranjeira FO, de Andrade KRC, Figueiredo ACMG, et al. Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS One. 2018; 13(4): e0194801. doi: 10.1371/journal.pone.0194801.

97. Gough SCL. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 2007; 77(1): 1 - 15. doi: 10.1016/j.diabres.2006.10.015.

98. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009; 11(4): 372 - 378. doi: 10.1111/j.1463-1326.2008.00976.x.

99. Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014; 349: g5459. doi: 10.1136/bmj.g5459.

100. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008; 25(4): 442 - 449. doi: 10.1111/j.1464-5491.2007.02407.x.

101. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther. 2011; 13 Suppl 1: S53 - S64. doi: 10.1089/dia.2011.0022.

102. Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015; 38(12): 2217 - 2225. doi: 10.2337/dc15-0249.

103. Cooke D, Bond R, Lawton J, et al. Structured type 1 diabetes education delivered within routine care: impact on glycemic control and diabetes-specific quality of life. Diabetes Care. 2013; 36(2): 270 - 272. doi: 10.2337/dc12-0080.

104. Cochran J, Conn VS. Meta-analysis of Quality of Life Outcomes Following Diabetes Self-management Training. Diabetes Educ. 2008; 34(5): 815 - 823. doi: 10.1177/0145721708323640.

105. Foster G, Taylor SJC, Eldridge SE, et al. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane Database Syst Rev. 2007; (4): CD005108. doi: 10.1002/14651858.CD005108.pub2.

106. Johnson TM, Murray MR, Huang Y. Associations Between Self-Management Education and Comprehensive Diabetes Clinical Care. Diabetes Spectr. 2010; 23(1): 41 - 46. doi: 10.2337/diaspect.23.1.41.

107. MacLeod J, Franz MJ, Handu D, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations. J Acad Nutr Diet. 2017; 117(10): 1637 - 1658. doi: 10.1016/j.jand.2017.03.023.

108. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002; 325(7367): 746. doi: 10.1136/bmj.325.7367.746.

109. Delahanty LM, Nathan DM, Lachin JM, et al. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr. 2009; 89(2): 518 - 524. doi: 10.3945/ajcn.2008.26498.

110. Laurenzi A, Bolla AM, Panigoni G, et al. Effects of Carbohydrate Counting on Glucose Control and Quality of Life Over 24 Weeks in Adult Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion: A randomized, prospective clinical trial (GIOCAR). Diabetes Care. 2011; 34(4): 823 - 827. doi: 10.2337/dc10-1490.

111. , , Bender R, et al. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia. 2005; 48(10): 1965 - 1970. doi: 10.1007/s00125-005-1905-1.

112. Bell KJ, Barclay AW, Petocz P, et al. Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2014; 2(2): 133 - 140. doi: 10.1016/S2213-8587(13)70144-X.

113. Elliott J, Lawton J, Rankin D, et al. The 5x1 DAFNE study protocol: a cluster randomised trial comparing a standard 5 day DAFNE course delivered over 1 week against DAFNE training delivered over 1 day a week for 5 consecutive weeks. BMC Endocr Disord. 2012; 12(1): 28. doi: 10.1186/1472-6823-12-28.

114. Haas L, Maryniuk M, Beck J, et al. National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2013; 36(Supplement_1): S100 - S108. doi: 10.2337/dc13-S100.

115. Майоров А.Ю., Мельникова О.Г., Котешкова О.М., и др. Техника инъекций и инфузии при лечении сахарного диабета. Методическое руководство. - ООО "АРТИНФО"; 2018.

116. Frid AH, Kreugel G, Grassi G, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016; 91(9): 1231 - 1255. doi: 10.1016/j.mayocp.2016.06.010.

117. Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BHR. Randomized Trial on the Influence of the Length of Two Insulin Pen Needles on Glycemic Control and Patient Preference in Obese Patients with Diabetes. Diabetes Technol Ther. 2011; 13(7): 737 - 741. doi: 10.1089/dia.2011.0010.

118. McKay M, Compion G, Lytzen L. A Comparison of Insulin Injection Needles on Patients' Perceptions of Pain, Handling, and Acceptability: A Randomized, Open-Label, Crossover Study in Subjects with Diabetes. Diabetes Technol Ther. 2009; 11(3): 195 - 201. doi: 10.1089/dia.2008.0054.

119. Birkebaek NH, Solvig J, Hansen B, et al. A 4-mm Needle Reduces the Risk of Intramuscular Injections Without Increasing Backflow to Skin Surface in Lean Diabetic Children and Adults. Diabetes Care. 2008; 31(9): e65. doi: 10.2337/dc08-0977.

120. Uzun S, Inanc N, Azal S. Determining optimal needle length for subcutaneous insulin injection. J Diab Nurs. 2001; 5(10): 83 - 87.

121. Hirsch LJ, Gibney MA, Albanese J, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010; 26(6): 1531 - 1541. doi: 10.1185/03007995.2010.482499.

122. Miwa T, Itoh R, Kobayashi T, et al. Comparison of the Effects of a New 32-Gaugex4-mm Pen Needle and a 32-Gaugex6-mm Pen Needle on Glycemic Control, Safety, and Patient Ratings in Japanese Adults with Diabetes. Diabetes Technol Ther. 2012; 14(12): 1084 - 1090. doi: 10.1089/dia.2012.0170.

123. Nagai Y, Ohshige T, Arai K, et al. Comparison Between Shorter Straight and Thinner Microtapered Insulin Injection Needles. Diabetes Technol Ther. 2013; 15(7): 550 - 555. doi: 10.1089/dia.2012.0334.

124. Bergenstal RM, Strock ES, Peremislov D, et al. Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes. Mayo Clin Proc. 2015; 90(3): 329 - 338. doi: 10.1016/j.mayocp.2014.12.014.

125. Kreugel G, Kees J, Jongbloed A, et al. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes. 2009; 58: A117.

126. Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004; 26(10): 1663 - 1678. doi: 10.1016/j.clinthera.2004.10.007.

127. Strauss K, Hannet I, McGonigle J, et al. Ultra-short (5 mm) insulin needles: Trial results and clinical recommendations. Pract Diabetes Int. 1999; 16(7): 218 - 222. doi: 10.1002/pdi.1960160711.

128. Hirsch L, Gibney M, Berube J, Manocchio J. Impact of a Modified Needle Tip Geometry on Penetration Force as Well as Acceptability, Preference, and Perceived Pain in Subjects with Diabetes. J Diabetes Sci Technol. 2012; 6(2): 328 - 335. doi: 10.1177/193229681200600216.

129. Sonoki K, Yoshinari M, Iwase M, et al. Regurgitation of Blood into Insulin Cartridges in the Pen-like Injectors. Diabetes Care. 2001; 24(3): 603 - 604. doi: 10.2337/diacare.24.3.603.

130. Shikata T, Karasawa T, Abe K, et al. Hepatitis B e Antigen and Infectivity of Hepatitis B Virus. J Infect Dis. 1977; 136(4): 571 - 576. doi: 10.1093/infdis/136.4.571.

131. Scioli D, Pizzella T, Vollaro L, et al. The action of VIRKON No Foam on the hepatitis B virus. Eur J Epidemiol. 1997; 13(8): 879 - 883. doi: 10.1023/A:1007399926095.

132. Herdman ML, Larck C, Schliesser SH, Jelic TM. Biological contamination of insulin pens in a hospital setting. Am J Health Syst Pharm. 2013; 70(14): 1244 - 1248. doi: 10.2146/ajhp120728.

133. Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract. 1992; 16(3): 209 - 212.

134. Johansson UB, Amsberg S, Hannerz L, et al. Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection Sites. Diabetes Care. 2005; 28(8): 2025 - 2027. doi: 10.2337/diacare.28.8.2025.

135. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003; 327(7411): 383 - 384. doi: 10.1136/bmj.327.7411.383.

136. Chantelau E, Lee DM, Hemmann DM, Zipfel U, Echterhoff S. What makes insulin injections painful? BMJ. 1991; 303(6793): 26 - 27. doi: 10.1136/bmj.303.6793.26.

137. Caffrey R. Are All Syringes Created Equal?: How to choose and use today's insulin syringes. Am J Nurs. 2003; 103(6): 46 - 49.

138. Braak EWT, Woodworth JR, Bianchi R, et al. Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin. Diabetes Care. 1996; 19(12): 1437 - 1440. doi: 10.2337/diacare.19.12.1437.

139. Lippert WC, Wall EJ. Optimal Intramuscular Needle-Penetration Depth. Pediatrics. 2008; 122(3): e556 - e563. doi: 10.1542/peds.2008-0374.

140. Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016; 39(11): 2065 - 2079. doi: 10.2337/dc16-1728.

141. U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. 2008.

142. Pickup JC. The Evidence Base for Diabetes Technology: Appropriate and Inappropriate Meta-Analysis. J Diabetes Sci Technol. 2013; 7(6): 1567 - 1574. doi: 10.1177/193229681300700617.

143. Lin MH, Connor CG, Ruedy KJ, et al. Race, Socioeconomic Status, and Treatment Center Are Associated with Insulin Pump Therapy in Youth in the First Year Following Diagnosis of Type 1 Diabetes. Diabetes Technol Ther. 2013; 15(11): 929 - 934. doi: 10.1089/dia.2013.0132.

144. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004; 27(7): 1554 - 1558. doi: 10.2337/diacare.27.7.1554.

145. Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008; 51(6): 941 - 951. doi: 10.1007/s00125-008-0974-3.

146. Karges B, Schwandt A, Heidtmann B, et al. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA. 2017; 318(14): 1358 - 1366. doi: 10.1001/jama.2017.13994.

147. Misso ML, Egberts KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010; (1): CD005103. doi: 10.1002/14651858.CD005103.pub2.

148. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin Pump Therapy: A meta-analysis. Diabetes Care. 2003; 26(4): 1079 - 1087. doi: 10.2337/diacare.26.4.1079.

149. , , , et al. Experiences and real life management of insulin pump therapy in adults with type 1 diabetes. Endocrinol Diabetes Nutr. 2019; 66(2): 117 - 123. doi: 10.1016/j.endinu.2018.05.017.

150. Peters AL, Ahmann AJ, Battelino T, et al. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(11): 3922 - 3937. doi: 10.1210/jc.2016-2534.

151. Meade LT, Rushton WE. Optimizing insulin pump therapy: a quality improvement project. Diabetes Educ. 2013; 39(6): 841 - 847. doi: 10.1177/0145721713504628.

152. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1): S181 - S206. doi: 10.2337/dc25-S009.

153. Gruessner AC, Sutherland DER. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin Transpl. 2008: 45 - 56.

154. Scalea JR, Butler CC, Munivenkatappa RB, et al. Pancreas Transplant Alone as an Independent Risk Factor for the Development of Renal Failure: A Retrospective Study. Transplantation. 2008; 86(12): 1789 - 1794. doi: 10.1097/TP.0b013e3181913fbf.

155. Всемирная Организация Здравоохранения. Терапевтическое обучение больных. Программы непрерывного обучения для работников здравоохранения в области профилактики хронических заболеваний. Отчет рабочей группы ВОЗ. Москва, 1998.

156. Deakin T, Whitham C. Structured patient education: the X-PERT Programme. Br J Community Nurs. 2009; 14(9): 398 - 404. doi: 10.12968/bjcn.2009.14.9.43916.

157. Старостина Е.Г., Анциферов М.Б., Галстян Г.Р., Дедов И.И. Эффективность программы интенсивного лечения и обучения больных сахарным диабетом 1 типа. Проблемы Эндокринологии. 1994; 40(3): 12 - 15. doi: 10.14341/probl12004.

158. American Diabetes Association Professional Practice Committee. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1): S86 - S127. doi: 10.2337/dc25-S005.

159. Yeoh E, Choudhary P, Nwokolo M, et al. Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2015; 38(8): 1592 - 1609. doi: 10.2337/dc15-0102.

160. Ellis SE, Speroff T, Dittus RS, et al. Diabetes patient education: a meta-analysis and meta-regression. Patient Educ Couns. 2004; 52(1): 97 - 105. doi: 10.1016/S0738-3991(03)00016-8.

161. Dickinson JK, Guzman SJ, Maryniuk MD, et al. The Use of Language in Diabetes Care and Education. Diabetes Care. 2017; 40(12): 1790 - 1799. doi: 10.2337/dci17-0041.

162. Davis J, Fischl AH, Beck J, et al. 2022 National Standards for Diabetes Self-Management Education and Support. Sci Diabetes Self-Manag Care. 2022; 48(1): 44 - 59. doi: 10.1177/26350106211072203.

163. Oliver L, Thompson G. The DAFNE Collaborative. Experiences of developing a nationally delivered evidence-based, quality-assured programme for people with type 1 diabetes. Pract Diabetes Int. 2009; 26(9): 371 - 377. doi: 10.1002/pdi.1424.

164. Майоров А.Ю., Мельникова О.Г., Филиппов Ю.И., и др. Структурированная программа обучения пациентов с сахарным диабетом 1-го типа. Учебно-методическое пособие для врачей и медицинских сестер по проведению терапевтического обучения пациентов "Школ для пациентов с сахарным диабетом". - Москва: ГНЦ ФГБУ "НМИЦ Эндокринологии" Минздрава России, 2023. - 160 с.

165. Tshiananga JKT, Kocher S, Weber C, Erny-Albrecht K, Berndt K, Neeser K. The effect of nurse-led diabetes self-management education on glycosylated hemoglobin and cardiovascular risk factors: a meta-analysis. Diabetes Educ. 2012; 38(1): 108 - 123. doi: 10.1177/0145721711423978.

166. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes. 2013; 6: 79 - 92. doi: 10.2147/DMSO.S37415.

167. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162 - 173. doi: 10.1016/S1474-4422(14)70251-0.

168. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013; 154(12): 2616 - 2625. doi: 10.1016/j.pain.2013.05.043.

169. Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life. Neurology. 2017; 88(20): 1958 - 1967. doi: 10.1212/WNL.0000000000003882.

170. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 6: CD007938. doi: 10.1002/14651858.CD007938.pub4.

171. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006; 67(8): 1411 - 1420. doi: 10.1212/01.wnl.0000240225.04000.1a.

172. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27(1): 151 - 162. doi: 10.1185/03007995.2010.537589.

173. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013; 36(5): 1384 - 1395. doi: 10.2337/dc12-2480.

174. Cryer PE. Diverse Causes of Hypoglycemia-Associated Autonomic Failure in Diabetes. N Engl J Med. 2004; 350(22): 2272 - 2279. doi: 10.1056/NEJMra031354.

175. Cryer PE, Preceded by: Cryer PE. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. - American Diabetes Association; 2016. https://www.worldcat.org/title/hypoglycemia-in-diabetes-pathophysiology-prevalenceand-prevention/oclc/953848679.

176. Slama G, Traynard PY, Desplanque N, et al. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solutin, or gel for the correction of insulin reactions. Arch Intern Med. 1990; 150(3): 589 - 593.

177. Agiostratidou G, Anhalt H, Ball D, et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017; 40(12): 1622 - 1630. doi: 10.2337/dc17-1624.

178. Karter AJ, Moffet HH, Liu JY, Lipska KJ. Surveillance of Hypoglycemia-Limitations of Emergency Department and Hospital Utilization Data. JAMA Intern Med. 2018; 178(7): 987 - 988. doi: 10.1001/jamainternmed.2018.1014.

179. Cox DJ, Kovatchev B, Koev D, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med. 2004; 11(4): 212 - 218. doi: 10.1207/s15327558ijbm1104_4.

180. Eli Lilly Canada Inc. Glucagon (rDNA Origin) Product Monograph. - Toronto, 2012.

181. Nordisk N. (glucagon) Product monograph. - Bagsvaerd, 2002.

182. Boido A, Ceriani V, Pontiroli AE. Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol. 2015; 52(2): 405 - 412. doi: 10.1007/s00592-014-0665-0.

183. Стандарт санаторно-курортной помощи больным сахарным диабетом. Проблемы стандартизации в здравоохранении. 2005; (1): 106 - 107.

184. Агасиев А.Р. Потребность больных сахарным диабетом в дополнительных лечебно-диагностических услугах при санаторно-курортном лечении. Современная медицина актуальные вопросы. 2015; (42 - 43): 93 - 97.

185. Приказ Минздрава РФ от 28.09.2020 N 1029Н "Об утверждении перечней медицинских показаний и противопоказаний для санаторно-курортного лечения".

186. American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1): S50 - S58. doi: 10.2337/dc25-S003.

187. Phillip M, Achenbach P, Addala A, et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care. 2024; 47(8): 1276 - 1298. doi: 10.2337/dci24-0042.

188. Приказ Министерства здравоохранения РФ от 13 марта 2023 г. N 104н "Об утверждении Порядка оказания медицинской помощи взрослому населению по профилю "эндокринология".

189. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol Chic Ill 1960. 1984; 102(4): 527 - 532.

190. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol Chic Ill 1960. 1984; 102(4): 520 - 526.

191. DCCT/EDIC Research Group, Nathan DM, Bebu I, et al. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med. 2017; 376(16): 1507 - 1516. doi: 10.1056/NEJMoa1612836.

192. American Diabetes Association. Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers. Clin Diabetes. 2022; 40(1): 10 - 38. doi: 10.2337/cd22-as01.

193. Misra A, Bachmann MO, Greenwood RH, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med. 2009; 26(10): 1040 - 1047. doi: 10.1111/j.1464-5491.2009.02820.x.

194. Mohamed Q, Gillies MC, Wong TY. Management of Diabetic Retinopathy: a systematic review. JAMA. 2007; 298(8): 902 - 916. doi: 10.1001/jama.298.8.902.

195. International Council of Ophthalmology. ICO Guidelines for Diabetic Eye Care. - 2017.

196. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(3): 412 - 418. doi: 10.2337/dc16-2641.

197. Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee, Hooper P, Boucher MC, et al. Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary. Can J Ophthalmol. 2012; 47(2): 91 - 96. doi: 10.1016/j.jcjo.2012.01.022.

198. Martin CL, Albers JW, Pop-Busui R. Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. 2014; 37(1): 31 - 38. doi: 10.2337/dc13-2114.

199. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136 - 154. doi: 10.2337/dc16-2042.

200. Eberle C, Stichling S. Clinical Improvements by Telemedicine Interventions Managing Type 1 and Type 2 Diabetes: Systematic Meta-review. J Med Internet Res. 2021; 23(2): e23244. doi: 10.2196/23244.

201. Hu Y, Wen X, Wang F, et al. Effect of telemedicine intervention on hypoglycaemia in diabetes patients: A systematic review and meta-analysis of randomised controlled trials. J Telemed Telecare. 2019; 25(7): 402 - 413. doi: 10.1177/1357633X18776823.

202. Tchero H, Kangambega P, Briatte C, et al. Clinical Effectiveness of Telemedicine in Diabetes Mellitus: A Meta-Analysis of 42 Randomized Controlled Trials. Telemed J E Health. 2019; 25(7): 569 - 583. doi: 10.1089/tmj.2018.0128.

203. Lee SWH, Ooi L, Lai YK. Telemedicine for the Management of Glycemic Control and Clinical Outcomes of Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Front Pharmacol. 2017; 8: 330. doi: 10.3389/fphar.2017.00330.

204. Wu C, Wu Z, Yang L, et al. Evaluation of the clinical outcomes of telehealth for managing diabetes: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2018; 97(43): e12962. doi: 10.1097/MD.0000000000012962.

205. Chase HP, Pearson JA, Wightman C, et al. Modem Transmission of Glucose Values Reduces the Costs and Need for Clinic Visits. Diabetes Care. 2003; 26(5): 1475 - 1479. doi: 10.2337/diacare.26.5.1475.

206. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012; 380(9854): 1662 - 1673. doi: 10.1016/S0140-6736(12)61350-6.

207. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80(1): 17 - 28. doi: 10.1038/ki.2010.483.

208. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1): S239 - S251. doi: 10.2337/dc25-S011.

209. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014; (6): CD007333. doi: 10.1002/14651858.CD007333.pub2.

210. Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010; 33(7): 1536 - 1543. doi: 10.2337/dc09-1098.

211. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998; 31(6): 954 - 961. doi: 10.1053/ajkd.1998.v31.pm9631839.

212. Murray DP, Young L, Waller J, et al. Is Dietary Protein Intake Predictive of 1-Year Mortality in Dialysis Patients? Am J Med Sci. 2018; 356(3): 234 - 243. doi: 10.1016/j.amjms.2018.06.010.

213. Volkert D, Beck AM, Cederholm T, et al. ESPEN practical guideline: Clinical nutrition and hydration in geriatrics. Clin Nutr. 2022; 41(4): 958 - 989. doi: 10.1016/j.clnu.2022.01.024.

214. Piccoli GB, Cederholm T, Avesani CM, et al. Nutritional status and the risk of malnutrition in older adults with chronic kidney disease - implications for low protein intake and nutritional care: A critical review endorsed by ERN-ERA and ESPEN. Clin Nutr. 2023; 42(4): 443 - 457. doi: 10.1016/j.clnu.2023.01.018.

215. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(5S): S1 - S127. doi: 10.1016/j.kint.2022.06.008.

216. Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020; 76(3 Suppl 1): S1 - S107. doi: 10.1053/j.ajkd.2020.05.006.

217. Ravel VA, Molnar MZ, Streja E, et al. Low protein nitrogen appearance as a surrogate of low dietary protein intake is associated with higher all-cause mortality in maintenance hemodialysis patients. J Nutr. 2013; 143(7): 1084 - 1092. doi: 10.3945/jn.112.169722.

218. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2004; (3): CD004937. doi: 10.1002/14651858.CD004937.

219. Mills KT, Chen J, Yang W, et al. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. JAMA. 2016; 315(20): 2200 - 2210. doi: 10.1001/jama.2016.4447.

220. Nilsson E, Gasparini A, , et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017; 245: 277 - 284. doi: 10.1016/j.ijcard.2017.07.035.

221. , Tikkanen HK, Forsblom C, et al. Leisure-time physical activity and development and progression of diabetic nephropathy in type 1 diabetes: the FinnDiane Study. Diabetologia. 2015; 58(5): 929 - 936. doi: 10.1007/s00125-015-3499-6.

222. Tikkanen-Dolenc H, , Forsblom C, et al. Physical Activity Reduces Risk of Premature Mortality in Patients With Type 1 Diabetes With and Without Kidney Disease. Diabetes Care. 2017; 40(12): 1727 - 1732. doi: 10.2337/dc17-0615.

223. DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol. 2014; 2(10): 793 - 800. doi: 10.1016/S2213-8587(14)70155-X.

224. DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011; 365(25): 2366 - 2376. doi: 10.1056/NEJMoa1111732.

225. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983; 1(8335): 1175 - 1179. doi: 10.1016/s0140-6736(83)92462-5.

226. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997; 349(9068): 1787 - 1792.

227. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017; 6(7): e005428. doi: 10.1161/JAHA.116.005428.

228. Sumida K, Molnar MZ, Potukuchi PK, et al. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. Clin J Am Soc Nephrol. 2017; 12(12): 1941 - 1949. doi: 10.2215/CJN.02720317.

229. Mauer M, Zinman B, Gardiner R, et al. Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. N Engl J Med. 2009; 361(1): 40 - 51. doi: 10.1056/NEJMoa0808400.

230. De Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022; 45(12): 3075 - 3090. doi: 10.2337/dci22-0027.

231. Su X, Zhang L, Lv J, et al. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016; 67(6): 881 - 892. doi: 10.1053/j.ajkd.2016.01.016.

232. Chewcharat A, Chewcharat P, Rutirapong A, Papatheodorou S. The effects of omega-3 fatty acids on diabetic nephropathy: A meta-analysis of randomized controlled trials. PLoS One. 2020; 15(2): e0228315. doi: 10.1371/journal.pone.0228315.

233. Ventura-Aguiar P, Cabello M, Beneyto I, et al. Patient and graft survival in pancreas transplant recipients: The EFISPAN study. Nefrologia (Engl Ed). 2023; 43(1): 133 - 143. doi: 10.1016/j.nefroe.2022.11.019.

234. Sung RS, Zhang M, Schaubel DE, et al. A Reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation. Transplantation. 2015; 99(9): 1900 - 1906. doi: 10.1097/TP.0000000000000663.

235. Lindahl JP, Hartmann A, Aakhus S, et al. Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation. Diabetologia. 2016; 59(4): 844 - 852. doi: 10.1007/s00125-015-3853-8.

236. Bunnapradist S, Cho YW, Cecka JM, Wilkinson A, Danovitch GM. Kidney allograft and patient survival in type I diabetic recipients of cadaveric kidney alone versus simultaneous pancreas kidney transplants: a multivariate analysis of the UNOS database. J Am Soc Nephrol. 2003; 14(1): 208 - 213. doi: 10.1097/01.asn.0000037678.54984.41.

237. Myint TM, O'Shaughnessy DV, Marshall S, et al. Health-related quality of life of patients awaiting kidney and simultaneous pancreas-kidney transplants. Nephrology (Carlton). 2013; 18(12): 827 - 832. doi: 10.1111/nep.12160.

238. Fujisawa-Tanaka C, Hiratsuka I, Shibata M, et al. Pancreas transplantation improves the quality of life of Japanese type 1 diabetes patients with diabetic kidney disease. Fujita Med J. 2023; 9(3): 194 - 199. doi: 10.20407/fmj.2022-019.

239. Stratta RJ, Fridell JA, Gruessner AC, et al. Pancreas transplantation: a decade of decline. Curr Opin Organ Transplant. 2016; 21(4): 386 - 392. doi: 10.1097/MOT.0000000000000319.

240. Benjamens S, Leemkuil M, Margreiter C, Huurman VA, Leuvenink HG, Pol RA. A steady decline in pancreas transplantation rates. Pancreatology. 2019; 19(1): 31 - 38. doi: 10.1016/j.pan.2018.11.003.

241. Alhamad T, Malone AF, Brennan DC, et al. Transplant Center Volume and the Risk of Pancreas Allograft Failure. Transplantation. 2017; 101(11): 2757 - 2764. doi: 10.1097/TP.0000000000001628.

242. Ассоциация врачей-офтальмологов, Российская ассоциация эндокринологов. Клинические рекомендации "Сахарный диабет: ретинопатия диабетическая, макулярный отек диабетический". 2023. Доступ по ссылке: https://cr.minzdrav.gov.ru/preview-cr/115_2.

243. Офтальмология: национальное руководство. 3-е изд, перераб. и доп. Под ред. Аветисова С.Э, Егорова Е.А. - Москва: ГЭОТАР-Медиа, 2024.

244. Giusti C, Gargiulo P. Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci. 2007; 11(3): 155 - 163.

245. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010 - 2022 гг. Сахарный Диабет. 2023; 26(2): 104 - 123. doi: 10.14341/DM13035.

246. Porta M, Kohner E. Screening for Diabetic Retinopathy in Europe. Diabet Med. 1991; 8(3): 197 - 198. doi: 10.1111/j.1464-5491.1991.tb01571.x.

247. Early Treatment Diabetic Retinopathy Study Research Group. Early Photocoagulation for Diabetic Retinopathy. Ophthalmology. 1991; 98(5): 766 - 785. doi: 10.1016/S0161-6420(13)38011-7.

248. Нероев В.В., Астахов Ю.С., Коротких С.А., и др. Протокол выполнения интравитреального введения лекарственных препаратов. Консенсус Экспертного совета по заболеваниям сетчатки и зрительного нерва Общероссийской общественной организации "Ассоциация врачей-офтальмологов". Вестник офтальмологии. 2020; 136(6): 251 - 263. doi: 10.17116/oftalma2020136062251.

249. International Diabetes Federation and The Fred Hollows Foundation. Diabetes Eye Health: A Guide for Health Care Professionals. International Diabetes Federation; 2015. www.idf.org/eyecare.

250. American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation Preferred Practice . 2020.

251. Public Health England. NHS diabetic eye screening (DES) programme. https://www.gov.uk/topic/population-screening-programmes/diabetic-eye.

252. NHS Scotland National Diabetes Retinopathy Screening. https://www.ndrs.scot.nhs.uk/Links/index.htm/.

253. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017; 237(4): 185 - 222. doi: 10.1159/000458539.

254. Virgili G, Menchini F, Casazza G, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev. 2015; 1(1): CD008081. doi: 10.1002/14651858.CD008081.pub3.

255. Tey KY, Teo K, Tan ACS, et al. Optical coherence tomography angiography in diabetic retinopathy: a review of current applications. Eye Vis (Lond). 2019; 6: 37. Published 2019 Nov 18. doi: 10.1186/s40662-019-0160-3.

256. Johannesen SK, Viken JN, Vergmann AS, Grauslund J. Optical coherence tomography angiography and microvascular changes in diabetic retinopathy: a systematic review. Acta Ophthalmol. 2019; 97(1): 7 - 14. doi: 10.1111/aos.13859.

257. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995; 44(8): 968 - 983.

258. World Health Organization. Prevention of Blindness from Diabetes Mellitus. Report of a WHO Consultation. Geneva, 2006.

259. Shi R, Zhao L, Wang F, et al. Effects of lipid-lowering agents on diabetic retinopathy: a Meta-analysis and systematic review. Int J Ophthalmol. 2018; 11(2): 287 - 295. doi: 10.18240/ijo.2018.02.18.

260. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The Lancet. 1998; 351(9095): 28 - 31. doi: 10.1016/S0140-6736(97)06209-0.

261. Mayer-Davis EJ, Bell RA, Reboussin BA, et al. Antioxidant nutrient intake and diabetic retinopathy. Ophthalmology. 1998; 105(12): 2264 - 2270. doi: 10.1016/S0161-6420(98)91227-1.

262. Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice . Ophthalmology. 2020; 127(1): P66 - P145. doi: 10.1016/j.ophtha.2019.09.025.

263. Бровкина А.Ф., Астахов Ю.С., ред. Руководство по клинической офтальмологии. - Медицинское информационное агентство, 2014.

264. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48(1 Suppl 1): S252 - S265. doi: 10.2337/dc25-S012.

265. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103(12): 1796 - 1806. doi: 10.1001/archopht.1985.01050120030015.

266. Brown Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015; 122(10): 2044 - 2052. doi: 10.1016/j.ophtha.2015.06.017.

267. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981; 88(7): 583 - 600.

268. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014; (11): CD011234. doi: 10.1002/14651858.CD011234.pub2.

269. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987; 27(4): 239 - 253. doi: 10.1097/00004397-198702740-00004.

270. Moutray T, Evans JR, Lois N, et al. Different lasers and techniques for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2018; 3: CD012314. doi: 10.1002/14651858.CD012314.pub2.

271. Gross JG, Glassman AR, Jampol LM, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy. JAMA. 2015; 314(20): 2137 - 2146. doi: 10.1001/jama.2015.15217.

272. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 1995; 38(6): 869 - 880. doi: 10.1002/ana.410380607.

273. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007; 370(9600): 1687 - 1697. doi: 10.1016/S0140-6736(07)61607-9.

274. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122(2): 375 - 381. doi: 10.1016/j.ophtha.2014.08.047.

275. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4): 789 - 801. doi: 10.1016/j.ophtha.2011.12.039.

276. Do D V, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119(8): 1658 - 1665. doi: 10.1016/j.ophtha.2012.02.010.

277. Boyer DS, Yoon YH, Belfort R, et al. Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. Ophthalmology. 2014; 121(10): 1904 - 1914. doi: 10.1016/j.ophtha.2014.04.024.

278. Wong TY, Haskova Z, Asik K, et al. Faricimab Treat-and-Extend for Diabetic Macular Edema. Ophthalmology. 2024; 131(6): 708 - 723. doi: 10.1016/j.ophtha.2023.12.026.

279. Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022; 238: 157 - 172. doi: 10.1016/j.ajo.2022.01.004.

280. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6): 1351 - 1359. doi: 10.1016/j.ophtha.2016.02.022.

281. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13): 1193 - 1203. doi: 10.1056/NEJMoa1414264.

282. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2): 171 - 185. doi: 10.1007/s10456-011-9249-6.

283. Flynn HW, Chew EY, Simons BD, et al. Pars Plana Vitrectomy in the Early Treatment Diabetic Retinopathy Study. Ophthalmology. 1992; 99(9): 1351 - 1357. doi: 10.1016/S0161-6420(92)31779-8.

284. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology. 1988; 95(10): 1307 - 1320. doi: 10.1016/s0161-6420(88)33015-0.

285. Piyasena MMPN, Murthy GVS, Yip JLY, et al. Systematic review and meta-analysis of diagnostic accuracy of detection of any level of diabetic retinopathy using digital retinal imaging. Syst Rev. 2018; 7(1): 182. doi: 10.1186/s13643-018-0846-y.

286. Callaghan BC, Kerber KA, Lisabeth LL, et al. Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy. JAMA Neurol. 2014; 71(9): 1143 - 1149. doi: 10.1001/jamaneurol.2014.1279.

287. Dyck PJ, Albers JW, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011; 27(7): 620 - 628. doi: 10.1002/dmrr.1226.

288. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care. 2002; 25(11): 2048 - 2052. doi: 10.2337/diacare.25.11.2048.

289. Bastyr EJ, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005; 27(8): 1278 - 1294. doi: 10.1016/j.clinthera.2005.08.002.

290. Xiong Q, Lu B, Ye H, et al. The Diagnostic Value of Neuropathy Symptom and Change Score, Neuropathy Impairment Score and Michigan Neuropathy Screening Instrument for Diabetic Peripheral Neuropathy. Eur Neurol. 2015; 74(5 - 6): 323 - 327. doi: 10.1159/000441449.

291. Meijer JWG, Smit AJ, Sonderen EV, et al. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002; 19(11): 962 - 965. doi: 10.1046/j.1464-5491.2002.00819.x.

292. Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012; 29(7): 937 - 944. doi: 10.1111/j.1464-5491.2012.03644.x.

293. Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006; 29(2): 340 - 344. doi: 10.2337/diacare.29.02.06.dc05-1549.

294. Jaiswal M, Lauer A, Martin CL, et al. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. Diabetes Care. 2013; 36(12): 3903 - 3908. doi: 10.2337/dc13-1213.

295. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006; 108(5): 477 - 481. doi: 10.1016/j.clineuro.2005.08.003.

296. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993; 36(2): 150 - 154. doi: 10.1007/BF00400697.

297. Spallone V, Morganti R, D'Amato C, et al. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012; 29(5): 578 - 585. doi: 10.1111/j.1464-5491.2011.03500.x.

298. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005; 64(2): 199 - 207. doi: 10.1212/01.WNL.0000149522.32823.EA.

299. Apfel SC, Asbury AK, Bril V, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001; 189(1 - 2): 3 - 5. doi: 10.1016/s0022-510x(01)00584-6.

300. Kim Y, Kim H, Choi S, et al. Clinical Usefulness of the Two-site Semmes-Weinstein Monofilament Test for Detecting Diabetic Peripheral Neuropathy. J Korean Med Sci. 2003; 18(1): 103 - 107. doi: 10.3346/jkms.2003.18.1.103.

301. Pham H, Armstrong DG, Harvey C, et al. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care. 2000; 23(5): 606 - 611. doi: 10.2337/diacare.23.5.606.

302. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve. 2010; 42(2): 157 - 164. doi: 10.1002/mus.21661.

303. Pop-Busui R, Cleary PA, Braffett BH, et al. Association Between Cardiovascular Autonomic Neuropathy and Left Ventricular Dysfunction. J Am Coll Cardiol. 2013; 61(4): 447 - 454. doi: 10.1016/j.jacc.2012.10.028.

304. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010; 33(10): 2285 - 2293. doi: 10.2337/dc10 - 1303.

305. Feldman EL, Stevens MJ, Thomas PK, et al. A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy. Diabetes Care. 1994; 17(11): 1281 - 1289. doi: 10.2337/diacare.17.11.1281.

306. Freeman R. Not all neuropathy in diabetes is of diabetic etiology: Differential diagnosis of diabetic neuropathy. Curr Diab Rep. 2009; 9(6): 423 - 431. doi: 10.1007/s11892-009-0069-7.

307. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014; 14(9): 528. doi: 10.1007/s11892-014-0528-7.

308. Freeman R, Durso-DeCruz E, Emir B. Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy. Diabetes Care. 2008; 31(7): 1448 - 1454. doi: 10.2337/dc07-2105.

309. Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017; 12(12): CD007963. doi: 10.1002/14651858.CD007963.pub3.

310. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010; 33(5): 1090 - 1096. doi: 10.2337/dc09-1941.

311. Chantelau EA, . Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly. 2014; 144: w13948. doi: 10.4414/smw.2014.13948.

312. Дедов И.И., Шестакова М.В.. Осложнения сахарного диабета: лечение и профилактика. - МИА; 2017.

313. Molines L, Darmon P, Raccah D. Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab. 2010; 36(4): 251 - 255. doi: 10.1016/j.diabet.2010.04.002.

314. Chantelau EA, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging--a review of 71 cases. Swiss Med Wkly. 2013; 143: w13831. doi: 10.4414/smw.2013.13831.

315. , , , et al. Advanced MR Imaging Techniques for Differentiation of Neuropathic Arthropathy and Osteomyelitis in the Diabetic Foot. RadioGraphics. 2017; 37(4): 1161 - 1180. doi: 10.1148/rg.2017160101.

316. Ertugrul BM, Lipsky BA, Savk O. Osteomyelitis or Charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem. Diabet Foot Ankle. 2013; 4(1): 21855. doi: 10.3402/dfa.v4i0.21855.

317. Chevalley T, Brandi ML, Cavalier E, et al. How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?. Osteoporos Int. 2021; 32(10): 1921 - 1935. doi: 10.1007/s00198-021-05957-9.

318. Rafiq S, Jeppesen PB. Is Hypovitaminosis D Related to Incidence of Type 2 Diabetes and High Fasting Glucose Level in Healthy Subjects: A Systematic Review and Meta-Analysis of Observational Studies. Nutrients. 2018; 10(1): 59. doi: 10.3390/nu10010059.

319. Greenhagen RM, Frykberg RG, Wukich DK. Serum vitamin D and diabetic foot complications. Diabet Foot Ankle. 2019; 10(1): 1579631. doi: 10.1080/2000625X.2019.1579631.

320. Удовиченко О.В., Бублик Е.В., Максимова Н.В., и др. Эффективность иммобилизирующих разгрузочных повязок Total Contact Cast: обзор зарубежных рандомизированных клинических исследований и собственные данные. Сахарный Диабет. 2010; 13(2): 50 - 55. doi: 10.14341/2072-0351-5674.

321. Christensen TM, Gade-Rasmussen B, Pedersen LW, et al. Duration of off-loading and recurrence rate in Charcot osteo-arthropathy treated with less restrictive regimen with removable walker. J Diabetes Complications. 2012; 26(5): 430 - 434. doi: 10.1016/j.jdiacomp.2012.05.006.

322. Game FL, Catlow R, Jones GR, et al. Audit of acute Charcot's disease in the UK: the CDUK study. Diabetologia. 2012; 55(1): 32 - 35. doi: 10.1007/s00125-011-2354-7.

323. Fernando M, Crowther R, Lazzarini P, et al. Biomechanical characteristics of peripheral diabetic neuropathy: A systematic review and meta-analysis of findings from the gait cycle, muscle activity and dynamic barefoot plantar pressure. Clin Biomech. 2013; 28(8): 831 - 845. doi: 10.1016/j.clinbiomech.2013.08.004.

324. Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev. 2024; 40(3): e3657. doi: 10.1002/dmrr.3657.

325. Cavanagh PR, Bus SA. Off-loading the diabetic foot for ulcer prevention and healing. Plast Reconstr Surg. 2011; 127 Suppl: 248S - 256S. doi: 10.1097/PRS.0b013e3182024864.

326. Guidelines (2023 update). IWGDF Guidelines. https://iwgdfguidelines.org/guidelines-2023/.

327. Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006; 55(12): 3556 - 3565. doi: 10.2337/db06-0653.

328. Soedamah-Muthu SS, Colhoun HM, Abrahamian H, et al. Trends in hypertension management in Type I diabetes across Europe, 1989/1990 - 1997/1999. Diabetologia. 2002; 45(10): 1362 - 1371. doi: 10.1007/s00125-002-0914-6.

329. Powers BJ, Olsen MK, Smith VA, et al. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011; 154(12): 781 - 788. doi: 10.7326/0003-4819-154-12-201106210-00005.

330. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5): 507 - 520. doi: 10.1001/jama.2013.284427.

331. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(9): 1273 - 1284. doi: 10.2337/dci17-0026.

332. , , , et al. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med. 2016; 13(3): e1001971. doi: 10.1371/journal.pmed.1001971.

333. Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004; 6(3): 116 - 125. doi: 10.1111/j.1524-6175.2004.03216.x.

334. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021 - 3104. doi: 10.1093/eurheartj/ehy339.

335. Министерство здравоохранения Российской Федерации. Клинические рекомендации "Артериальная гипертензия у взрослых". 2024. Доступ по ссылке: https://cr.minzdrav.gov.ru/preview-cr/62_3.

336. Shibao C, Lipsitz LA, Biaggioni I. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013; 7(4): 317 - 324. doi: 10.1016/j.jash.2013.04.006.

337. Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017; 264(8): 1567 - 1582. doi: 10.1007/s00415-016-8375-x.

338. Gaspar L, Kruzliak P, Komornikova A, et al. Orthostatic hypotension in diabetic patients-10-year follow-up study. J Diabetes Complications. 2016; 30(1): 67 - 71. doi: 10.1016/j.jdiacomp.2015.08.020.

339. Vistisen D, Andersen GS, Hansen CS, et al. Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine. Circulation. 2016; 133(11): 1058 - 1066. doi: 10.1161/CIRCULATIONAHA.115.018844.

340. Rawshani A, Sattar N, , et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018; 392(10146): 477 - 486. doi: 10.1016/S0140-6736(18)31506-X.

341. Miller RG, Costacou T, Orchard TJ. Risk Factor Modeling for Cardiovascular Disease in Type 1 Diabetes in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study: A Comparison With the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Diabetes. 2019; 68(2): 409 - 419. doi: 10.2337/db18-0515.

342. McGurnaghan SJ, McKeigue PM, Read SH, et al. Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia. 2021; 64(9): 2001 - 2011. doi: 10.1007/s00125-021-05478-4.

343. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; 45(36): 3415 - 3537. doi: 10.1093/eurheartj/ehae177.

344. Marx N, Federici M, , et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043 - 4140. doi: 10.1093/eurheartj/ehad192.

345. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255 - 323. doi: 10.1093/eurheartj/ehz486.

346. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73(24): e285 - e350. doi: 10.1016/j.jacc.2018.11.003.

347. Бойцов С.А., Погосова Н.В., Бубнова М.Г., и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский Кардиологический Журнал. 2018; 23(6): 7 - 122. doi: 10.15829/1560-4071-2018-6-7-122.

348. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 Diabetes Mellitus and Cardiovascular Disease. Circulation. 2014; 130(13): 1110 - 1130. doi: 10.1161/CIR.0000000000000034.

349. Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM; DCCT/EDIC Research Group. Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. 2019; 42(7): 1284 - 1289. doi: 10.2337/dc18-1613.

350. Rawshani A, Rawshani A, Sattar N, et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation. 2019; 139(16): 1900 - 1912. doi: 10.1161/CIRCULATIONAHA.118.037454.

351. Tell S, Nadeau KJ, Eckel RH. Lipid management for cardiovascular risk reduction in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2020; 27(4): 207 - 214. doi: 10.1097/MED.0000000000000551.

352. Leiter LA, Cariou B, , et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017; 19(12): 1781 - 1792. doi: 10.1111/dom.13114.

353. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012; 125(3): 505 - 513. doi: 10.1161/CIRCULATIONAHA.111.059022.

354. Valgimigli M, Campo G, Monti M, et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial. Circulation. 2012; 125(16): 2015 - 2026. doi: 10.1161/CIRCULATIONAHA.111.071589.

355. Schulz-Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015; 36(20): 1252 - 1263. doi: 10.1093/eurheartj/ehu523.

356. Han Y, Xu B, Xu K, et al. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial. Circ Cardiovasc Interv. 2016; 9(2): e003145. doi: 10.1161/CIRCINTERVENTIONS.115.003145.

357. Hong SJ, Shin DH, Kim JS, et al. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. JACC Cardiovasc Interv. 2016; 9(14): 1438 - 1446. doi: 10.1016/j.jcin.2016.04.036.

358. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018; 53(1): 34 - 78. doi: 10.1093/ejcts/ezx334.

359. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357(20): 2001 - 2015. doi: 10.1056/NEJMoa0706482.

360. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010; 375(9711): 283 - 293. doi: 10.1016/S0140-6736(09)62191-7.

361. Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019; 394(10204): 1169 - 1180. doi: 10.1016/S0140-6736(19)31887-2.

362. Anand SS, Eikelboom JW, Dyal L, et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019; 73(25): 3271 - 3280. doi: 10.1016/j.jacc.2019.02.079.

363. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006; 333(7571): 726. doi: 10.1136/bmj.38947.697558.AE.

364. Han Y, Liao Z, Li Y, et al. Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-Induced Gastrointestinal Injury. J Am Coll Cardiol. 2022; 79(2): 116 - 128. doi: 10.1016/j.jacc.2021.10.028.

365. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018; 3(4): 231 - 241. doi: 10.1016/S2468-1253(18)30037-2.

366. Moayyedi P, Eikelboom JW, Bosch J, et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019; 157(2): 403 - 412.e5. doi: 10.1053/j.gastro.2019.04.041.

367. ООО "Российское кардиологическое общество", АНО "Национальное общество по изучению атеросклероза", НП "Национальное общество по атеротромбозу", и др. Клинические рекомендации "Стабильная ишемическая болезнь сердца". 2024. Доступ по ссылке: https://cr.minzdrav.gov.ru/preview-cr/155_2.

368. Pandey A, Vaduganathan M, Patel KV, et al. Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. JACC Heart Fail. 2021; 9(3): 215 - 223. doi: 10.1016/j.jchf.2020.10.013.

369. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022; 45(7): 1670 - 1690. doi: 10.2337/dci22-0014.

370. Галявич А.С., Терещенко С.Н., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(11): 6162. https://doi.org/10.15829/1560-4071-2024-6162.

371. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599 - 3726. doi: 10.1093/eurheartj/ehab368.

372. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., et al. Сердечная недостаточность: хроническая и острая декомпенсированная. Диагностика, профилактика и лечение. Кардиология. 2018; 58(6S): 8 - 158. doi: 10.18087/cardio.2475.

373. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017; 70(6): 776 - 803. doi: 10.1016/j.jacc.2017.04.025.

374. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129 - 2200. doi: 10.1093/eurheartj/ehw128.

375. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005; 7(4): 537 - 541. doi: 10.1016/j.ejheart.2005.01.022.

376. Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015; 350: h910. doi: 10.1136/bmj.h910.

377. Mayer CC, Schmaderer C, Loutradis C, et al. Heart Failure and Atrial Fibrillation Modify the Associations of Nocturnal Blood Pressure Dipping Pattern With Mortality in Hemodialysis Patients. Hypertension. 2020; 76(4): 1231 - 1239. doi: 10.1161/HYPERTENSIONAHA.120.15420.

378. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006; 56(526): 327 - 333.

379. McCullough PA, Nowak RM, McCord J, et al. B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study. Circulation. 2002; 106(4): 416 - 422. doi: 10.1161/01.CIR.0000025242.79963.4C.

380. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009; 13(32): 1-iii. doi: 10.3310/hta13320.

381. Yamada T, Shojima N, Noma H, et al. Sodium glucose co transporter 2 inhibitors as add on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta analysis of randomized controlled trials. Diabetes Obes Metab. 2018; 20(7): 1755 - 1761. doi: 10.1111/dom.13260.

382. Fattah H, Vallon V. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. Drugs. 2018; 78(7): 717 - 726. doi: 10.1007/s40265-018-0901-y.

383. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007; 50(1): 18 - 25. doi: 10.1007/s00125-006-0491-1.

384. Morbach S, Furchert H, , et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012; 35(10): 2021 - 2027. doi: 10.2337/dc12-0200.

385. Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016; 63(2 Suppl): 3S - 21S. doi: 10.1016/j.jvs.2015.10.003.

386. Hart T, Milner R, Cifu A. Management of a Diabetic Foot. JAMA. 2017; 318(14): 1387 - 1388. doi: 10.1001/jama.2017.11700.

387. National Institute for Health and Clinical Excellence. Diabetic Foot Problems. Inpatient Management of Diabetic Foot Problems. - London, 2011.

388. Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. BMJ. 1982; 284(6320): 928 - 930. doi: 10.1136/bmj.284.6320.928.

389. Feinglass J, Shively VP, Martin GJ, et al. How 'preventable' are lower extremity amputations? A qualitative study of patient perceptions of precipitating factors. Disabil Rehabil. 2012; 34(25): 2158 - 2165. doi: 10.3109/09638288.2012.677936.

390. Ababneh M, Al Ayed MY, Robert AA, Al Dawish MA. Clinical Utility of the Ankle-Brachial Index and Toe Brachial Index in Patients with Diabetic Foot Ulcers. Curr Diabetes Rev. 2020; 16(3): 270 - 277. doi: 10.2174/1573399815666190531093238.

391. Huen KH, Chowdhury R, Shafii SM, et al. Smoking Cessation Is the Least Successful Outcome of Risk Factor Modification in Uninsured Patients with Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2015; 29(1): 42 - 49. doi: 10.1016/j.avsg.2014.09.014.

392. Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643 - 2653. doi: 10.1056/NEJMoa052187.

393. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733): 2215 - 2222. doi: 10.1016/S0140-6736(10)60484-9.

394. Momsen AH, Jensen MB, Norager CB, et al. Drug Therapy for Improving Walking Distance in Intermittent Claudication: A Systematic Review and Meta-analysis of Robust Randomised Controlled Studies. Eur J Vasc Endovasc Surg. 2009; 38(4): 463 - 474. doi: 10.1016/j.ejvs.2009.06.002.

395. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670 - 1681. doi: 10.1016/S0140-6736(10)61350-5.

396. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010; 303(9): 841 - 848. doi: 10.1001/jama.2010.221.

397. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840. doi: 10.1136/bmj.a1840.

398. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118): 1755 - 1762. doi: 10.1016/s0140-6736(98)04311-6.

399. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315 - 2381. doi: 10.1093/eurheartj/ehw106.

400. Российское общество сердечно-сосудистых хирургов России, Российское общество ангиологов и сосудистых хирургов, Российское общество хирургом, Российское кардиологическое общество, Российская ассоциация эндокринологов. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей. - Москва, 2019.

401. Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014; 59(1): 220 - 34. e342. doi: 10.1016/j.jvs.2013.08.003.

402. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000; 19 Suppl A.

403. Collins R, Burch J, Cranny G, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ. 2007; 334(7606): 1257. doi: 10.1136/bmj.39217.473275.55.

404. Dominguez A 3rd, Bahadorani J, Reeves R, et al. Endovascular therapy for critical limb ischemia. Expert Rev Cardiovasc Ther. 2015; 13(4): 429 - 444. doi: 10.1586/14779072.2015.1019472.

405. Manzi M, Palena L, Cester G. Endovascular techniques for limb salvage in diabetics with crural and pedal disease. J Cardiovasc Surg (Torino). 2011; 52(4): 485 - 492.

406. Madabhushi V, Davenport D, Jones S, et al. Revascularization of intermittent claudicants leads to more chronic limb-threatening ischemia and higher amputation rates. J Vasc Surg. 2021; 74(3): 771 - 779. doi: 10.1016/j.jvs.2021.02.045.

407. Levin SR, Farber A, Cheng TW, et al. Patients undergoing interventions for claudication experience low perioperative morbidity but are at risk for worsening functional status and limb loss. J Vasc Surg. 2020; 72(1): 241 - 249. doi: 10.1016/j.jvs.2019.08.278.

408. Ерошенко А.В., Минушкина Л.О., Ерошкин И.А., Зубова Е.А. Реваскуляризация или консервативная терапия при перемежающейся хромоте - систематический обзор и метаанализ клинических исследований с периодом наблюдения 5 лет и более. Международный Журнал Интервенционной Кардиоангиологии. 2024; 76: 45 - 74.

409. Belch JJ, Dormandy J; CASPAR Writing Committee, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010; 52(4): 825 - 833. e8332. doi: 10.1016/j.jvs.2010.04.027.

410. Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30(2): 192 - 201. doi: 10.1093/eurheartj/ehn534.

411. Monteiro-Soares M, Boyko EJ, Ribeiro J, et al. Predictive factors for diabetic foot ulceration: a systematic review. Diabetes Metab Res Rev. 2012; 28(7): 574 - 600. doi: 10.1002/dmrr.2319.

412. Crawford F, Cezard G, Chappell FM, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess. 2015; 19(57): 1 - 210. doi: 10.3310/hta19570.

413. Monteiro-Soares M, Russell D, Boyko EJ, et al. Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3273. doi: 10.1002/dmrr.3273.

414. Mayor J, Chung J, Zhang Q, et al. Using the Society for Vascular Surgery Wound, Ischemia, and foot Infection classification to identify patients most likely to benefit from revascularization. J Vasc Surg. 2019; 70(3): 776 - 785. e1. doi: 10.1016/j.jvs.2018.11.039.

415. Hinchliffe RJ, Forsythe RO, Apelqvist J, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3276. doi: 10.1002/dmrr.3276.

416. Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med. 2018; 35(1): 78 - 88. doi: 10.1111/dme.13537.

417. Tan TW, Shih CD, Concha-Moore KC, et al. Disparities in outcomes of patients admitted with diabetic foot infections. PLoS One. 2019; 14(2): e0211481. doi: 10.1371/journal.pone.0211481.

418. Zha ML, Cai JY, Chen HL. A Bibliometric Analysis of Global Research Production Pertaining to Diabetic Foot Ulcers in the Past Ten Years. J Foot Ankle Surg. 2019; 58(2): 253 - 259. doi: 10.1053/j.jfas.2018.08.052.

419. Peters EJ, Lipsky BA. Diagnosis and management of infection in the diabetic foot. Med Clin North Am. 2013; 97(5): 911 - 946. doi: 10.1016/j.mcna.2013.04.005.

420. Lavery LA, Peters EJ, Armstrong DG, Wendel CS, Murdoch DP, Lipsky BA. Risk factors for developing osteomyelitis in patients with diabetic foot wounds. Diabetes Res Clin Pract. 2009; 83(3): 347 - 352. doi: 10.1016/j.diabres.2008.11.030.

421. Sotto A, Richard JL, Jourdan N, et al. Miniaturized Oligonucleotide Arrays. Diabetes Care. 2007; 30(8): 2051 - 2056. doi: 10.2337/dc07 - 0461.

422. , Lipsky BA, Abbas ZG, et al. Diagnosis of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36(S1): e3281. doi: 10.1002/dmrr.3281.

423. Peters EJG, Lipsky BA, , et al. Interventions in the management of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36(S1): e3282. doi: 10.1002/dmrr.3282.

424. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis. 2006; 42(1): 57 - 62. doi: 10.1086/498112.

425. Ertugrul MB, Baktiroglu S, Salman S, et al. Pathogens isolated from deep soft tissue and bone in patients with diabetic foot infections. J Am Podiatr Med Assoc. 2008; 98(4): 290 - 295. doi: 10.7547/0980290.

426. Noor S, Raghav A, Parwez I, et al. Molecular and culture based assessment of bacterial pathogens in subjects with diabetic foot ulcer. Diabetes Metab Syndr. 2018; 12(3): 417 - 421. doi: 10.1016/j.dsx.2018.03.001.

427. Percival SL, Malone M, Mayer D, Salisbury AM, Schultz G. Role of anaerobes in polymicrobial communities and biofilms complicating diabetic foot ulcers. Int Wound J. 2018; 15(5): 776 - 782. doi: 10.1111/iwj.12926.

428. , , , , , Molines-Barroso RJ. Cortical disruption is the most reliable and accurate plain radiographic sign in the diagnosis of diabetic foot osteomyelitis. Diabet Med. 2019; 36(2): 258 - 259. doi: 10.1111/dme.13824.

429. O'Meara S, Nelson EA, Golder S, et al. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet Med. 2006; 23(4): 341 - 347. doi: 10.1111/j.1464-5491.2006.01830.x.

430. Ramanujam CL, Han D, Zgonis T. Medical Imaging and Laboratory Analysis of Diagnostic Accuracy in 107 Consecutive Hospitalized Patients With Diabetic Foot Osteomyelitis and Partial Foot Amputations. Foot Ankle Spec. 2018; 11(5): 433 - 443. doi: 10.1177/1938640017750255.

431. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis. 2008; 47(4): 519 - 527. doi: 10.1086/590011.

432. Cohen M, Cerniglia B, Gorbachova T, Horrow J. Added value of MRI to X-ray in guiding the extent of surgical resection in diabetic forefoot osteomyelitis: a review of pathologically proven, surgically treated cases. Skeletal Radiol. 2019; 48(3): 405 - 411. doi: 10.1007/s00256-018-3045-y.

433. Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. Diabetes Care. 2017; 40(8): 1111 - 1120. doi: 10.2337/dc17-0532.

434. Weinstein D, Wang A, Chambers R, Stewart CA, Motz HA. Evaluation of magnetic resonance imaging in the diagnosis of osteomyelitis in diabetic foot infections. Foot Ankle. 1993; 14(1): 18 - 22. doi: 10.1177/107110079301400104.

435. Bus SA. The Role of Pressure Offloading on Diabetic Foot Ulcer Healing and Prevention of Recurrence. Plast Reconstr Surg. 2016; 138(3 Suppl): 179S - 187S. doi: 10.1097/PRS.0000000000002686.

436. Fernando ME, Crowther RG, Pappas E, et al. Plantar pressure in diabetic peripheral neuropathy patients with active foot ulceration, previous ulceration and no history of ulceration: a meta-analysis of observational studies. PLoS One. 2014; 9(6): e99050. Published 2014 Jun 10. doi: 10.1371/journal.pone.0099050.

437. Jeffcoate W, Game F, Turtle-Savage V, et al. Evaluation of the effectiveness and cost-effectiveness of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes: a randomised controlled trial. Health Technol Assess. 2017; 21(34): 1 - 92. doi: 10.3310/hta21340.

438. Piaggesi A, Goretti C, Iacopi E, et al. Comparison of Removable and Irremovable Walking Boot to Total Contact Casting in Offloading the Neuropathic Diabetic Foot Ulceration. Foot Ankle Int. 2016; 37(8): 855 - 861. doi: 10.1177/1071100716643429.

439. Bus SA, van Netten JJ, Kottink AI, et al. The efficacy of removable devices to offload and heal neuropathic plantar forefoot ulcers in people with diabetes: a single-blinded multicentre randomised controlled trial. Int Wound J. 2018; 15(1): 65 - 74. doi: 10.1111/iwj.12835.

440. Gordon KA, Lebrun EA, Tomic-Canic M, Kirsner RS. The role of surgical debridement in healing of diabetic foot ulcers. Skinmed. 2012; 10(1): 24 - 26.

441. Митиш В.А., Ерошкин И.А., Галстян Г.Р., и др. Гнойно-некротические поражения нейроишемической формы синдрома диабетической стопы. Новые возможности комплексного хирургического лечения. Эндокринная хирургия. 2008; 2(1): 15 - 19. doi: 10.14341/2306-3513-2008-1-15-19.

442. Caputo WJ, Beggs DJ, DeFede JL, Simm L, Dharma H. A prospective randomised controlled clinical trial comparing hydrosurgery debridement with conventional surgical debridement in lower extremity ulcers. Int Wound J. 2008; 5(2): 288 - 294. doi: 10.1111/j.1742-481X.2007.00490.x.

443. Jeffcoate WJ, Bus SA, Game FL, et al. Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality. Lancet Diabetes Endocrinol. 2016; 4(9): 781 - 788. doi: 10.1016/S2213-8587(16) 30012-2.

444. Vas P, Rayman G, Dhatariya K, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3284. doi: 10.1002/dmrr.3284.

445. Lipsky BA, , Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3280. doi: 10.1002/dmrr.3280.

446. Selva Olid A, , Barajas-Nava LA, Gianneo OD, Bonfill Cosp X, Lipsky BA. Systemic antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev. 2015; 2015(9): CD009061. doi: 10.1002/14651858.CD009061.pub2.

447. Jongsma H, Bekken JA, Akkersdijk GP, Hoeks SE, Verhagen HJ, Fioole B. Angiosome-directed revascularization in patients with critical limb ischemia. J Vasc Surg. 2017; 65(4): 1208 - 1219. e1. doi: 10.1016/j.jvs.2016.10.100.

448. Lo ZJ, Lin Z, Pua U, et al. Diabetic Foot Limb Salvage-A Series of 809 Attempts and Predictors for Endovascular Limb Salvage Failure. Ann Vasc Surg. 2018; 49: 9 - 16. doi: 10.1016/j.avsg.2018.01.061.

449. Lejay A, Georg Y, Tartaglia E, et al. Long-term outcomes of direct and indirect below-the-knee open revascularization based on the angiosome concept in diabetic patients with critical limb ischemia. Ann Vasc Surg. 2014; 28(4): 983 - 989. doi: 10.1016/j.avsg.2013.08.026.

450. Hinchliffe RJ, Brownrigg JR, Andros G, et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab Res Rev. 2016; 32 Suppl 1: 136 - 144. doi: 10.1002/dmrr.2705.

451. Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol. 2012; 21(4): 187 - 194. doi: 10.1055/s-0032-1330232.

452. Capell WH, Bonaca MP, Nehler MR, et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018; 199: 83 - 91. doi: 10.1016/j.ahj.2018.01.011.

453. Foley TR, Singh GD, Kokkinidis DG, et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2017; 6(7): e005699. doi: 10.1161/JAHA.117.005699.

454. Yang Q, Zhang Y, Yin H, Lu Y. Topical Recombinant Human Epidermal Growth Factor for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Clinical Trials. Ann Vasc Surg. 2020; 62: 442 - 451. doi: 10.1016/j.avsg.2019.05.041.

455. Berlanga-Acosta J, , , et al. Diabetic Foot Ulcers and Epidermal Growth Factor: Revisiting the Local Delivery Route for a Successful Outcome. Biomed Res Int. 2017; 2017: 2923759. doi: 10.1155/2017/2923759.

456. Lavery LA, Murdoch DP, Kim PJ, Fontaine JL, Thakral G, Davis KE. Negative Pressure Wound Therapy With Low Pressure and Gauze Dressings to Treat Diabetic Foot Wounds. J Diabetes Sci Technol. 2014; 8(2): 346 - 349. doi: 10.1177/1932296813519012.

457. Liu Z, Dumville JC, Hinchliffe RJ, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev. 2018; 10(10): CD010318. doi: 10.1002/14651858.CD010318.pub3.

458. Зайцева Е.Л., Доронина Л.П., Молчков Р.В., и др. Влияние терапии отрицательным давлением на репаративные процессы в мягких тканях нижних конечностей у пациентов с нейропатической и нейроишемической формами синдрома диабетической стопы. Сахарный диабет. 2014; 17(3): 113 - 121. doi: 10.14341/DM20143113-121.

459. Bonner T, Foster M, Spears-Lanoix E. Type 2 diabetes-related foot care knowledge and foot self-care practice interventions in the United States: a systematic review of the literature. Diabet Foot Ankle. 2016; 7: 29758. doi: 10.3402/dfa.v7.29758.

460. van Netten JJ, Raspovic A, Lavery LA, et al. Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3270. doi: 10.1002/dmrr.3270.

461. Szpunar SM, Minnick SE, Dako I, Saravolatz LD 2nd. Improving Foot Examinations in Patients With Diabetes: A Performance Improvement Continuing Medical Education (PI-CME) Project. Diabetes Educ. 2014; 40(3): 281 - 289. doi: 10.1177/0145721714526789.

462. Donohoe ME, Fletton JA, Hook A, et al. Improving foot care for people with diabetes mellitus--a randomized controlled trial of an integrated care approach. Diabet Med. 2000; 17(8): 581 - 587. doi: 10.1046/j.1464-5491.2000.00336.x.

463. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007; 30(7): 1920 - 1925. doi: 10.2337/dc07-0278.

464. Charron-Prochownik D, Sereika SM, Becker D, et al. Long-term effects of the booster-enhanced READY-Girls preconception counseling program on intentions and behaviors for family planning in teens with diabetes. Diabetes Care. 2013; 36(12): 3870 - 3874. doi: 10.2337/dc13-0355.

465. Peterson C, Grosse SD, Li R, et al. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol. 2015; 212(1): 74. e1 - 74. e749. doi: 10.1016/j.ajog.2014.09.009.

466. Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari LA, Esmaeil SA. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2010; 10: 63. doi: 10.1186/1471-2393-10-63.

467. Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001; 94(8): 435 - 444. doi: 10.1093/qjmed/94.8.435.

468. Wahabi HA, Esmaeil SA, Fayed A, Al-Shaikh G, Alzeidan RA. Pre-existing diabetes mellitus and adverse pregnancy outcomes. BMC Res Notes. 2012; 5: 496. doi: 10.1186/1756-0500-5-496.

469. Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009; 32(6): 1046 - 1048. doi: 10.2337/dc08-2061.

470. Nielsen GL, , . HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006; 29(12): 2612 - 2616. doi: 10.2337/dc06-0914.

471. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia. 2000; 43(1): 79 - 82. doi: 10.1007/s001250050010.

472. Maresh MJ, Holmes VA, Patterson CC, et al. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care. 2015; 38(1): 34 - 42. doi: 10.2337/dc14-1755.

473. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012; 60(2): 444 - 450. doi: 10.1161/HYPERTENSIONAHA.112.196352.

474. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015; 350: h1035. doi: 10.1136/bmj.h1035.

475. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000; 23(8): 1084 - 1091. doi: 10.2337/diacare.23.8.1084.

476. Damm JA, Asbjornsdottir B, Callesen NF, et al. Diabetic Nephropathy and Microalbuminuria in Pregnant Women With Type 1 and Type 2 Diabetes: Prevalence, antihypertensive strategy, and pregnancy outcome. Diabetes Care. 2013; 36(11): 3489 - 3494. doi: 10.2337/dc13-1031.

477. Ringholm L, Damm JA, Vestgaard M, Damm P, Mathiesen ER. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep. 2016; 16(2): 12. doi: 10.1007/s11892-015-0705-3.

478. Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006; 19(5): 513 - 519. doi: 10.1016/j.amjhyper.2005.12.010.

479. Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011; 6(11): 2587 - 2598. doi: 10.2215/CJN.10841210.

480. Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol. 2003; 189(2): 507 - 512. doi: 10.1067/s0002-9378(03)00497-6.

481. Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study. Am J Obstet Gynecol. 1991; 164(1 Pt 1): 103 - 111. doi: 10.1016/0002-9378(91)90637-7.

482. Lemaitre M, Faiz K, Baudoux F, et al. Intermittently scanned continuous glucose monitoring is associated with lower spontaneous abortion rate compared with conventional blood glucose monitoring in pregnant women with type 1 diabetes: An observational study. Diab Vasc Dis Res. 2022; 19(6): 14791641221136837. doi: 10.1177/14791641221136837.

483. O'Neill SM, Kenny LC, Khashan AS, et al. Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev. 2017; 2(2): CD011880. doi: 10.1002/14651858.CD011880.pub2.

484. Farrar D, Tuffnell DJ, West J, West HM. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2016; 2016(6): CD005542. Published 2016 Jun 7. doi: 10.1002/14651858.CD005542.pub3.

485. Ho YR, Wang P, Lu MC, et al. Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women. PLoS One. 2017; 12(5): e0177563. doi: 10.1371/journal.pone.0177563.

486. Lowe LP, Metzger BE, Dyer AR, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: Associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012; 35(3): 574 - 580. doi: 10.2337/dc11-1687.

487. Inkster ME, Fahey TP, Donnan PT, et al. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies. BMC Pregnancy Childbirth. 2006; 6(1): 30. doi: 10.1186/1471-2393-6-30.

488. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Suppl 1): S282 - S294. doi: 10.2337/dc24-S015.

489. McElvy SS, Miodovnik M, Rosenn B, et al. A focused preconceptional and early pregnancy program in women with Type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med. 2000; 9(1): 14 - 20. doi: 10.1002/(SICI)1520-6661(200001/02)9:1<14::AID-MFM5>3.0.CO;2-K.

490. Murphy HR, Roland JM, Skinner TC, et al. Effectiveness of a Regional Prepregnancy Care Program in Women With Type 1 and Type 2 Diabetes: Benefits beyond glycemic control. Diabetes Care. 2010; 33(12): 2514 - 2520. doi: 10.2337/dc10-1113.

491. Elixhauser A, Weschler JM, Kitzmiller JL, et al. Cost-Benefit Analysis of Preconception Care for Women With Established Diabetes Mellitus. Diabetes Care. 1993; 16(8): 1146 - 1157. doi: 10.2337/diacare.16.8.1146.

492. Tieu J, Middleton P, Crowther CA, Shepherd E. Preconception care for diabetic women for improving maternal and infant health. Cochrane Database Syst Rev. 2017; 8: CD007776. doi: 10.1002/14651858.CD007776.pub3.

493. Письмо МЗ РФ от 18 июня 2024 г. N 30-4/2753 "О вакцинации против COVID-19".

494. Приказ Министерства здравоохранения Российской Федерации от 06.12.2021 N 1122н "Об утверждении национального календаря профилактических прививок, календаря профилактических прививок по эпидемическим показаниям и порядка проведения профилактических прививок".

495. Goeijenbier M, van Sloten TT, Slobbe L, et al. Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine. 2017; 35(38): 5095 - 5101. doi: 10.1016/j.vaccine.2017.07.095.

496. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of Influenza Vaccine in Health Care Professionals. JAMA. 1999; 281(10): 908 - 913. doi: 10.1001/jama.281.10.908.

497. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000; 355(9198): 93 - 97. doi: 10.1016/S0140-6736(99)05190-9.

498. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med. 1996; 156(14): 1546 - 1550.

499. Simpson CR, Lone NI, Kavanagh K, et al. Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. BMJ Open. 2017; 7(2): e014200. doi: 10.1136/bmjopen-2016-014200.

500. Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017; 75(5): 381 - 394. doi: 10.1016/j.jinf.2017.09.010.

501. Darvishian M, van den Heuvel ER, Bissielo A, et al. Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies. Lancet Respir Med. 2017; 5(3): 200 - 211. doi: 10.1016/S2213-2600(17)30043-7.

502. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015; 13(1): 53. doi: 10.1186/s12916-015-0295-6.

503. Demurtas J, Celotto S, Beaudart C, et al. The efficacy and safety of influenza vaccination in older people: An umbrella review of evidence from meta-analyses of both observational and randomized controlled studies. Ageing Res Rev. 2020; 62: 101118. doi: 10.1016/j.arr.2020.101118.

504. Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care. 2000; 23(1): 95 - 108. doi: 10.2337/diacare.23.1.95.

505. Чучалин А.Г., Брико Н.И., Авдеев С.Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019; 29(1): 19 - 34. doi: 10.18093/0869-0189-2019-29-1-19-34.

506. Tin Tin Htar M, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017; 12(5): e0177985. doi: 10.1371/journal.pone.0177985.

507. Isturiz R, Webber C. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults. Hum Vaccines Immunother. 2015; 11(7): 1825 - 1827. doi: 10.1080/21645515.2015.1043502.

508. Webber C, Patton M, Patterson S, et al. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017; 35(9): 1266 - 1272. doi: 10.1016/j.vaccine.2017.01.032.

509. LeBlanc JJ, ElSherif M, Ye L, et al. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). Vaccine. 2019; 37(36): 5466 - 5473. doi: 10.1016/j.vaccine.2019.05.003.

510. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal adults 60 - 64 years of age. Vaccine. 2014; 32(20): 2364 - 2374. doi: 10.1016/j.vaccine.2014.02.002.

511. Paradiso PR. Pneumococcal Conjugate Vaccine for Adults: A New Paradigm. Clin Infect Dis. 2012; 55(2): 259 - 264. doi: 10.1093/cid/cis359.

512. Feld J, Janssen A, Abbas Z, et al. Глобальные Практические Рекомендации Всемирной Гастроэнтерологической Организации. Гепатит B. - World Gastroenterology Organisation, 2015.

513. Van Der Meeren O, Crasta P, Cheuvart B, De Ridder M. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis. Hum Vaccines Immunother. 2015; 11(7): 1725 - 1728. doi: 10.1080/21645515.2015.1039758.

514. Van Den Ende C, Marano C, Van Ahee A, et al. The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017; 16(8): 811 - 832. doi: 10.1080/14760584.2017.1338568.

515. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003; 63(10): 1021 - 1051. doi: 10.2165/00003495-200363100-00006.

516. Van Der Meeren O, Peterson JT, Dionne M, et al. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Hum Vaccines Immunother. 2016; 12(8): 2197 - 2203. doi: 10.1080/21645515.2016.1164362.

517. Elhanan E, Boaz M, Schwartz I, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-VacTM, as compared to , among vaccine and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018; 22(1): 151 - 158. doi: 10.1007/s10157-017-1416-7.

518. Hoseini Tavassol Z, Sajjadpour Z, Hasani-Ranjbar S, et al. Do patients with diabetic foot ulcer need booster dose of tetanus vaccine? J Diabetes Metab Disord. 2022; 21(1): 1023 - 1027. doi: 10.1007/s40200-021-00966-1.

519. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003; 51(10): 1451 - 1454. doi: 10.1046/j.1532-5415.2003.51465.x.